Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. - Pi-Sunyer,F.X.; Aronne,L.J.; Heshmati,H.M.; Devin,J.; Rosenstock,J. (JAMA, 2006)